Cas:1862-07-3 6-(Dimethylamino)-1-hexanol manufacturer & supplier

Chemical Name:6-(Dimethylamino)-1-hexanol

CAS.NO:1862-07-3

Synonyms:MFCD00046028;6-Dimethylamino-1-hexanol;6-(Dimethylamino)hexan-1-ol;1-HEXANOL,6-(DIMETHYLAMINO);6-(N,N-dimethylamino)-1-hexanol;6-dimethylamino-l-hexanol;6-(Dimethylamino)-1-hexanol;1-Hexanol, 6-(dimethylamino)-;6-(N,N-dimethylamino)hexan-1-ol;1-Hexanol, 6- (dimethylamino)-;N,N-dimethyl-6-amino-1-hexanol;6-Dimethyl amino hexanol-1;6-(dimethylamino)hexanol

Molecular Formula:C₈H₁₉NO

Molecular Weight:145.243

HS Code:2922199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:203.8±23.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.449

PSA:23.47000

Exact Mass:145.146667

LogP:0.71

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2733

Packing Group:

Contact us for information like MFCD00046028 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-(dimethylamino)hexanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-(N,N-dimethylamino)-1-hexanol Use and application,6-(Dimethylamino)-1-hexanol technical grade,usp/ep/jp grade.

Related News: China is now dealing with another disease outbreak �� this one mostly affecting animals but also potentially deadly among people. 6-(Dimethylamino)-1-hexanol manufacturer Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 6-(Dimethylamino)-1-hexanol supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 6-(Dimethylamino)-1-hexanol vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 6-(Dimethylamino)-1-hexanol factory Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).